Good morning. My name is Madison, and I will be your conference operator today. At this time, I would like to Welcome everyone to Harmony Biosciences' Q1 2024 Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question at that time, please press star One on your telephone keypad. Please be advised that today's conference may be recorded. Lastly, if you should need operator assistance, please press star 0. I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead. Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences' Q1 2024 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP-to-non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance. Our speakers on today's call are Dr. Jeffrey Dayno, President and CEO; Jeffrey Dierks, Chief Commercial Officer; Dr. Kumar Budur, Chief Medical Officer; and Sandip Kapadia, Chief Financial Officer and Chief Administrative Officer. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details. We have a lot to share this morning, so in order to allow ample time for Q&A, we will keep our prepared remarks brief this morning. I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff? Thank you, Luis, and thanks everyone for joining our conference call today. Earlier this morning, we were excited to announce our third business development deal in the past eight months with the acquisition of Epygenix Therapeutics. As you may have seen in our earnings release, in addition to this news, we have accelerated our growth strategy and have transformed our business to position Harmony for long-term value creation. Given all the exciting news and upcoming catalysts that we have to share today, we will not be able to go into depth on everything on this call, but the key points that I want you to take away from our call today regarding the Harmony story are the following: our commercial business is strong, and WAKIX continues to demonstrate durable growth now year five in the market. WAKIX is a $1 billion-plus market opportunity in adult narcolepsy alone, and we are well on our way as we expect to continue to grow the brand through LOE in 2030. We are growing organically by advancing our life cycle management programs for pitolisant with the next-generation formulations designed to improve the patient experience and patient outcomes, as well as generate new IP to extend the pitolisant franchise out beyond 2040. We are also pursuing new indications for pitolisant, including near-term catalysts in pediatric narcolepsy and idiopathic hypersomnia, to help even more patients living with unmet medical needs and drive incremental revenue. We are making good progress toward pediatric exclusivity, which would provide an additional six months of regulatory protection on the back end of our longest patent, a commercial opportunity of upward around $1 billion. We are growing inorganically through business development. With our previous announcement regarding the licensing of TPM-1116, a highly potent and selective orexin-2 receptor agonist, to solidify and grow our sleep-like franchise, and today's announcement regarding the acquisition of Epygenix and their rare epilepsy portfolio, we now have three orphan-rare CNS franchises in late-stage development, each with potential peak sales opportunities of $1-$2 billion and patent protection ranging from the late 2030s to mid-2040s. At Harmony, we believe we are well positioned to become the leading patient-focused CNS biotechnology company delivering innovative treatments to patients with unmet medical needs and, while doing so, drive significant and durable value creation. I want to take a minute to emphasize the value of our pipeline that we have been building. Across these three franchises, we are currently working with eight assets being studied across 13 development programs. More importantly, we expect these programs to result in at least one new product or indication launch each year over the next five years. We have planned ahead, executed smart and strategic business development deals with low upfront costs and risks tied to the achievement of certain clinical, regulatory, and sales milestones that, if successful, are poised to generate significant near-term and long-term value creation. And we are not stopping here. While we have made significant progress on our business development goals, we continue to look to build out our pipeline even further. While we do a broad sweep of the BD landscape, our focus is on assets in the orphan-rare CNS space consistent with the three deals we have done over the past eight months. We feel there are other opportunities out there that would fit our growth strategy. With approximately $454 million in cash and cash equivalents in investments as of March 31st, we are in a solid financial position to execute on additional BD opportunities and have demonstrated our ability to do so. Let me share a few highlights with you from each of our three franchises that are in late-stage development. First, building off our leadership position in sleep-wake with WAKIX. We began working on extending the pitolisant franchise several years ago by developing new formulations of pitolisant that are planned to come to the market both during and towards the end of the WAKIX life cycle. Importantly, these products are designed to improve patient experience and patient outcomes and will have new IP that extends our durable growth and leadership in sleep-wake out beyond 2040. We remain committed to the idiopathic hypersomnia patient community and gaining an indication for pitolisant in IH, and plan to submit an SNDA to FDA in the second half of this year. After following the orexin space for the last few years and doing diligence on several of the assets, we licensed TPM-1116, a highly potent, selective oral orexin-2 receptor agonist with a potential best-in-class profile due to its unique chemical structure and preclinical data. This solidifies our leadership position in sleep medicine and demonstrates our long-term commitment to the field. Our second franchise in rare neurobehavioral disorders continues to make good progress, and the lead program with ZYN-002 is in a pivotal phase III registrational trial for Fragile X syndrome and on track for top-line data readout in mid-2025. With approximately 80,000 patients living with Fragile X in the US, this is a sizable market opportunity, and we also have global rights to this asset with even bigger market potential. Today, with the announcement of our latest BD deal, the acquisition of Epygenix Therapeutics, we established a rare epilepsy franchise and acquired two new assets to serve as the foundation of what could be a larger franchise. The lead program is with clemizole hydrochloride, or EPX-100, which has received both orphan drug designation and rare pediatric disease designation from the FDA for Dravet syndrome and Lennox-Gastaut syndrome. It is currently in a pivotal registrational trial for Dravet syndrome with top-line data expected in 2026. We also plan to start a pivotal phase III trial with EPX-100 in patients with Lennox-Gastaut syndrome in the second half of this year. Kumar will be providing more color on the growth of our development enterprise and our robust pipeline programs later in the call. The important takeaway is that we expect these programs to result in at least one new product or indication launch each year over the next five years with multi-billion dollar revenue potential extending out beyond 2040. While I have focused on the significant progress in our catalyst-rich pipeline that has the ability to deliver durable growth out beyond 2040, I don't want you to lose sight of the continued durable growth that WAKIX has demonstrated now year five in the market. We delivered another strong quarter with net revenues of $154.6 million, which represents 30% growth year over year. With these strong results, we are reiterating our 2024 net revenue guidance of $700-$720 million. We believe that we can continue to grow the franchise for years to come and remain confident that WAKIX represents a $1 billion-plus opportunity in adult narcolepsy alone, and we are well on our way. With that, I will turn the call over to Jeffrey Dierks, our Chief Commercial Officer, for an update on our commercial performance in our sleep-wake franchise. Jeff? Thanks, Jeff. The Q1 was another strong quarter for WAKIX in adult narcolepsy, highlighted by continued product adoption and growth in our underlying business fundamentals. Net sales for the quarter were $154.6 million, representing 30% growth from the same quarter previous year. The solid net sales performance in the Q1 reaffirms our confidence in our net sales guidance of $700-$720 million for the full year of 2024. Key drivers of our performance in the quarter were continued growth in the average patients on WAKIX, growth in the WAKIX prescriber base, and continued strong favorable market access as seen on slides five and six. The average number of patients on WAKIX increased to approximately 6,300 in the Q1. We are extremely pleased with the continued growth in patients on WAKIX and the durability we are seeing in that growth in year 5 of our rare orphan commercialization. We successfully navigated the traditional Q1 seasonal payer dynamics and Change Healthcare cybersecurity impact, and are seeing good leading indicators in our underlying business fundamentals heading into the Q2. We saw continued growth of the WAKIX prescriber base beyond oxybate writers in the Q1 as well. We saw meaningful growth in new writers of WAKIX in the approximately 5,000 non-oxybate REMS-enrolled healthcare professional audience and are more than 33% writer-penetrated in the segment at the end of the Q1. This audience represents an insulated group of prescribers and patients from the oxybates, and the continued growth in prescribers in the segment each quarter reaffirms WAKIX is growing the branded narcolepsy segment beyond the oxybates by providing a meaningfully differentiated product profile and one that offers broad clinical utility across the entire narcolepsy treating healthcare professional universe. In addition to the growth in new prescribers, we continue to see growth in the depth of prescribing among the approximately 4,000 oxybate REMS-enrolled healthcare professionals, even with the availability of new and generic oxybate options. WAKIX is highly penetrated within this prescriber audience and see growth in the segment each quarter as WAKIX is being prescribed to additional narcolepsy patients. Our ability to call in the entire narcolepsy treating healthcare professional audience allows us to tap into the full diagnosed narcolepsy patient opportunity, giving us confidence in the long-term future growth of WAKIX. The last driver of our performance in the Q1 was the continued strong and favorable market access coverage for WAKIX, even with the availability of new and generic oxybate options on the market. We've seen no changes to the overall payer coverage for WAKIX over the past year, and we believe we are well positioned to support future growth. In summary, we had another strong quarter of durable growth in performance in net sales, patient adds, and growth in prescribers of WAKIX. We're seeing good leading indicators on our underlying business fundamentals heading into the Q2, and the solid performance in Q1 reaffirms our confidence in our full-year net sales guidance of $700 million-$720 million. I'm excited about our performance, and we are confident in WAKIX representing a potential billion-dollar-plus opportunity in adult narcolepsy alone, and we are well on our way. I would like to now turn the call over to our Chief Medical Officer, Kumar Budur, to discuss the advancements in our clinical development programs. Kumar? Thank you, Jeff. Good morning, everyone, and thank you for joining us today. We are making great progress in advancing, expanding, and diversifying our pipeline programs, several of which are in late-stage development. As Jeff mentioned, we now have 13 different development programs ranging from preclinical to registration studies across 8 different assets and under 3 distinct franchises focused on rare orphan neuroindications with high unmet needs and with the ability to launch a number of these indications in the coming years. Our full clinical development pipeline is shown on slide 7, and I think you can appreciate how much it has grown over the past year. Let me start by sharing some key updates in each of our franchises, starting with our growth in sleep-wake franchise and our program in idiopathic hypersomnia. We met with the FDA in March to discuss the next steps for our IH program. We were encouraged by the discussions we had with the agency on our data, the burden of the disease, limitations of current treatment options, and the off-label use of scheduled drugs. We feel the agency understands and appreciates the high unmet need in IH. While we understand the bar for approval is high, we are moving forward and plan to submit an SNDA in the second half of 2024. The submission will be based on the totality of the data generated from the Intune study, including data from the ongoing long-term extension study, which strongly supports pitolisant's efficacy in patients with IH. We have also identified other supporting information that will be included in the SNDA to further strengthen our submission. We are optimistic and remain committed in bringing a new treatment option to patients living with IH that is not scheduled, has an established safety profile, and a simple dosing regimen. Moving to pediatric narcolepsy, we are on track for the PDUFA date of June 21st. We are pleased with the FDA's decision to grant priority review. This decision highlights the need for new treatment options for the approximately 4,000 pediatric patients living with narcolepsy. For Prader-Willi syndrome, we initiated this phase III Tempo study in the Q1. This is a global, multi-center double-blind randomized placebo-controlled study that will randomize approximately 134 patients in either pitolisant or placebo in a 1:1 ratio. We are committed to obtaining pediatric exclusivity for pitolisant. We are making good progress on the two requirements: data in pediatric narcolepsy and data in PWS patients by submitting pediatric narcolepsy SNDA and initiating the phase III study in PWS, respectively. Obtaining pediatric exclusivity will add 6 months of regulatory exclusivity to the backend of the longest patent, and this represents a significant commercial opportunity for WAKIX. An important element of our franchise growth strategy is to develop new pitolisant-based assets with the goal of generating new IP, extending the pitolisant franchise beyond 2040, and bringing new and improved versions of pitolisant to the market for people living with narcolepsy and other sleep-wake disorders. We are making good progress on these formulations, NextGen-1 NG1 and NextGen-2 NG2, with our partner, Bioprojet. We are pleased to report positive PK data in NG1 and enteric-coated pitolisant formulation designed to demonstrate bioequivalence to WAKIX through an abbreviated development pathway. The NG1 formulation is designed to potentially decrease GI side effects and also have an important additional clinical differentiation compared to WAKIX. That is, the ability to start dosing at 17.8 milligrams at the beginning of the therapeutic dose range for pitolisant rather than the need to titrate up to the therapeutic range. This clinical differentiation will be supported by a dosing optimization study. As shown on slide 9, the pilot B study showed similar rate and extent of absorption, that is, CMAX and AUC, between NG1 and WAKIX, demonstrating relative bioavailability. The next steps for NG1 include initiating the pivotal bioequivalence and dosing optimization studies in the Q4 of this year. Based on the development timeline, we expect a PDUFA date in 2026. In addition, a provisional patent for NG1 has been filed and the potential for patent protection out to 2044. Moving on to NextGen-2 or NG2, this is an enhanced formulation of pitolisant designed to deliver an optimized PK profile and a higher dosage strength. This formulation will have a new IP and full development program and is expected to launch towards the end of WAKIX life cycle. We are on track to report PK data from this formulation in the first half of this year. We are also very pleased to continue to strengthen our leadership position in sleep-wake with licensing of TPM-1116. Licensing an orexin asset was a natural next step for us as it leverages our established experience and expertise both in development and commercialization of treatments for sleep-wake disorders. TPM-1116, a novel orexin-2 receptor agonist, represents a potential best-in-class product profile amongst the current orexin-2 receptor agonists. It has a new chemical scaffold compared to the other orexin-2 receptor agonists, potentially contributing to its unique product profile. TPM-1116 will be evaluated for the treatment of narcolepsy and other sleep-wake disorders. The preclinical data suggests its potential best-in-class profile based on its high potency, good selectivity, potential for once-daily dosing, and good safety profile. We look forward to sharing the preclinical data at an upcoming scientific conference. In terms of development milestones, we expect to file an IND in mid-2025 and initiate first-in-human studies in the second half of 2025. Moving on to our next franchise, the neurobehavioral disorders franchise, ZYN-002, a pharmaceutically manufactured synthetic cannabidiol gel, devoid of THC, with a patent-protected permeation-enhanced gel for transdermal delivery, which, like WAKIX, could be a foundational asset in our growing neurobehavioral franchise. We are currently enrolling patients in the pivotal phase III ReConnect trial in Fragile X syndrome. With approximately 80,000 patients diagnosed with Fragile X syndrome in the U.S. alone and no approved treatments, there is significant unmet medical need. We expect to complete patient enrollment in the Q1 of 2025 with top-line data in mid-2025. ZYN-002 was also studied in an open-label phase II proof of concept study, the INSPIRE study, in patients with 22q deletion syndrome and generated positive signals in aberrant behavioral checklists. This represents another opportunity to help approximately 80,000 patients with 22q deletion syndrome in the U.S. alone, and we have been interacting with the FDA about a phase III program in 22q and expanding this franchise. It is worth noting, ZYN-002 is a global opportunity for Harmony, and we look forward to exploring ex-US opportunities to bring this novel treatment to patients living with Fragile X syndrome and 22q deletion syndrome around the world. Finally, we announced today the establishment of our third rare orphan neuro franchise in epilepsy with the acquisition of Epygenix Therapeutics. This acquisition brings us two assets targeting rare epilepsies, both global opportunities for us. The first asset, EPX-100, is clemizole hydrochloride, a potent oral centrally acting serotonin agonist, which is currently in a pivotal registration and clinical trial for the treatment of Dravet syndrome in children and adults. Dravet syndrome is a rare and severe developmental epileptic encephalopathy with high unmet medical need. The proven mechanism of action of clemizole via the serotonergic system could offer good efficacy and, importantly, a safer product profile than currently available treatment options and improve the quality of life and functioning in patients with DS. The schematic of the trial design for this registration study, known as the Argus study, is shown on slide 11. We anticipate top-line data from the Argus study in 2026. EPX-100 is also poised to enter a phase III registration trial for the treatment of Lennox-Gastaut syndrome, another rare and severe developmental epileptic encephalopathy with high unmet medical need. We anticipate starting this study in the second half of 2024. EPX-100 has received both orphan drug designations and rare pediatric disease designations from the FDA for both Dravet syndrome and Lennox-Gastaut syndrome. A second investigational product, EPX-200, is a potent oral centrally acting selective 5-HT2C agonist that is currently in IND-enabling studies. EPX-200 also received orphan drug designations for Dravet syndrome and Lennox-Gastaut syndrome, as well as rare pediatric disease designations for Lennox-Gastaut syndrome. To conclude, we have made tremendous progress in advancing our development programs, expanding our pipeline, and diversifying our portfolio, resulting in multiple late-stage development programs across three different franchises: sleep-wake, neurobehavioral, and rare epilepsy. If successful, these programs could result in at least one new product or indication launch every year over the next five years, along with the potential to help hundreds of thousands of patients across all the rare neurological disorders we are investigating. I'm proud of the hard work and dedication of our teams at Harmony and look forward to sharing additional updates as we continue to advance our clinical development programs. On behalf of Harmony, I would like to thank all the patients and their families for participating in our clinical trials, as well as clinical investigators and site personnel for their efforts and commitment in helping us advance our development programs. I'll now turn the call over to our CFO, Sandip Kapadia, for an update on our financial performance. Sandip? Thank you, Kumar, and good morning, everyone. This morning, we issued our Q1 earnings release and filed our 10-Q, where you'll find the details of our Q1 2024 financial and operating results. Our financial performance is also shown on slides 12 through 15. We're off to a great start to the year in 2024. We reported another strong quarter of growth in revenues and net income, along with continued cash generation. Our unique financial performance and profile positions us well to continue advancing our growth strategy and look for opportunities to drive value for shareholders. We reported net revenues of $154.6 million compared to $119.1 million in the prior year quarter, representing a growth of 30%. Performance in the quarter reflects the continued strong underlying demand for WAKIX, coupled with the typical seasonality dynamics that the industry as a whole experiences each year in Q1, including higher growth-to-net deductions, along with a couple of days of drawdown in trade inventories. We also reported strong growth in net income and margins. Non-GAAP-adjusted net income for the Q1 of 2024 was $50.7 million or $0.88 per diluted share, compared to $40.7 million or $0.67 per diluted share in the prior year quarter. We believe non-GAAP-adjusted net income better reflects the underlying business performance. Please refer to our press release for a reconciliation of GAAP to non-GAAP results. We ended the Q1 with $453.6 million of cash equivalents and investments on the balance sheet. The balance reflects continued cash generation of our underlying business, which provides us the financial flexibility to continue executing on business development and opportunistically returning capital to shareholders via our share repurchase program. Looking ahead, we continue to expect strong quarter-over-quarter growth with a potential for trade inventory drawdown of a few days in Q2 as we head into the summer. We are reiterating our net revenue guidance of 2024 of $700 million-$720 million, highlighting our progress towards the $1 billion+ opportunity in narcolepsy alone. With respect to expenses, we do expect to take IPR&D charges for the licensing of TPM-1116 and the acquisition of Epygenix in the Q2. The charges will primarily consist of the upfront cost of $25.5 million and $35 million, respectively, offset by the value of net assets we have acquired. In addition, we expect ongoing operating expenses of approximately $35 million for 2024 as we advance both programs. As you saw from the terms of both transactions, we continue to be disciplined with capital deployment. We structured both transactions with low upfront payments, with success-driven regulatory and sales milestones. As a result of our recent efforts in business development, we now have multiple programs in late-stage development with the potential to generate revenue in the coming years. So, in conclusion, we're off to a great start to the year, along with strong outlook for the balance of the year and well-positioned to continue to drive value for shareholders. And with that, I'd like to turn the call back to Jeff for his closing remarks. Jeff? Thank you, Sandip. As we have just highlighted for you, Harmony is a growth story, and our growth is accelerating. We have strategically been executing on expanding our pipeline and diversifying our portfolio to drive near-term revenue out to 2030 and durable long-term revenue growth out beyond 2040. The key drivers of our catalyst-rich pipeline and future revenue potential include the next-gen formulations of pitolisant that can generate new IP and extend the pitolisant franchise and drive durable revenue out beyond 2040, new indications for pitolisant, including near-term catalysts in pediatric narcolepsy and idiopathic hypersomnia, gaining pediatric exclusivity, and an additional six months of patent protection on the back end of our longest patent, which represents a significant commercial opportunity. Our three business development deals over the past eight months have resulted in three orphan rare CNS franchises in late-stage development, each with potential peak sales opportunities of $1-$2 billion and patent protection ranging from the late 2030s to mid-2040s. The growth of our development enterprise, which now includes eight assets, is advancing across 13 development programs, resulting in the potential for at least one new product or indication launched each year over the next five years. At Harmony, we believe we are well-positioned to become the leading patient-focused CNS biotech company delivering innovative treatments to patients with unmet medical needs and, while doing so, drive significant and durable value creation. Thank you for your attention, and I will now turn the call over to the operator for Q&A. Operator? Thank you. At this time, if you would like to ask a question, please press star one on your telephone keypad. If you wish to remove yourself from the queue, you may do so by pressing star two. We remind you to please pick up your handset and please limit yourself to one question and one follow-up question. We will take our first question from Charles Duncan with Cantor Fitzgerald. Hey, good morning, Jeff and team. Thanks for taking our questions, and congratulations on good commercial quarter as well as recent business development deals, impressive activity. Thank you, Charles. So I had a quick question for Jeff Dierks in terms of the commercial business. Nice growth year-over-year, appreciating the seasonal issues. But in terms of the number of patient adds, let me ask you about how you feel about that, as well as one of the things that Kumar mentioned is in the next generation, an ability to titrate more rapidly. And I guess I'm wondering, if you look at the current patient population taking WAKIX, how do you feel that's impacting the use of WAKIX? Will the improved titration rate make a difference in terms of the persistence within WAKIX? Thanks. Yeah, Charles, thank you for your question. Jeff, you want to? Sure. Yeah, thanks for the question, Charles. To answer your question on the average number of patient adds in the Q1, first off, I'll tell you we're extremely pleased with the durable growth that we're seeing in the average number of patients. It grew 150 patients sequentially from what we reported in Q4. We continue to see strong top-line demand and new patient starts. And Charles, as you know, the 150 average patient growth is well in line with our past 2 Q1 average patient growths in the last 2 years. And as you cited, we typically have the Q1 seasonal payer dynamics, the reauthorizations of prescriptions. And a reminder, coming into 2024, we had a larger established patient base. We had 6,150 average patients coming into 2024, whereas a year ago, we only had about 4,900. All of those established patients are exposed to those reauthorizations that occur every January for specialty and branded products. And certainly, Charles, you know those reauthorizations just simply add time. So about 25% more of our patients were exposed to that. And then on top of that, we did have the additional headwind of Change Healthcare. But as you know, we've got a great commercial model. We have a closed distribution network. And the outstanding work of our team, we did a tremendous job in navigating those dynamics. And we've continued to be able to demonstrate growth every single quarter in average patients. We're going to continue to tap into that large patient opportunity as the market allows each quarter. And we're confident, as Sandip shared in his prepared comments, to see quarter-over-quarter growth for the remainder of 2024 and beyond. That's helpful. If I could ask one development question that is regarding the new assets, Epygenix, congratulations on that. Kumar, you mentioned 2026 being data with EPX-100. I guess I'm wondering, what is really modulating that timing of 2026? I know these are difficult studies to enroll, but could that prove to be an overly conservative estimate of time to top-line data on EPX-100? Good morning, Charles. Thanks for the question. Look, we just acquired this asset. And right now, we believe 2026 is when we will be able to come out with the top-line data, obviously, as the study progresses, as we are able to bring in Harmony resources, the expertise in R&D, and especially the advocacy support group that we have very well established here at Harmony, who work hand-in-hand with patient communities. So all of these things will definitely help with the recruitment. And you're right. Recruiting DS patients is not necessarily easy, but I think we have a really A-plus team to recruit these patients. And as we make progress with the clinical trial, we will provide more granularity for the timeline. Okay. Thank you for taking our questions. Thank you. We will take our next question from François Brisebois with Oppenheimer. Hi. And I apologize if the question was already asked. I got dropped off the call for a sec there. But I was just wondering, in terms of the acquisition, the Epygenix acquisition, is there any data that's shared that you intend to share soon about other past readouts, just given it's a private company and people might not be familiar with the story? Good morning, Frank. Thank you for your question. I think, yeah, Kumar can talk about data generated and what we'll be sharing going forward. Yeah. Thank you, Frank. Yes. I mean, clemizole hydrochloride, Frank, is a first-generation antihistamine that was introduced in the 1950s and sunset in the 1970s, introduction of second- and third-generation antihistamines. There is some safety data from that period of time, which is very benign. And then the SCN1A mutation model of zebrafish, where clemizole hydrochloride was studied, is published extensively by Scott Baraban, who's a professor at the University of California in San Francisco. The mechanism of action, Frank, is a potent centrally acting serotonergic drug. And this is a proven mechanism of action when it comes to developmental epileptic encephalopathies. So that, alongside with the robust data that we observed in the SCN1A mutation zebrafish model and the safety data that we have from clemizole, most of it is available in the public domain. And within the clinical trial, this is a phase III registrational clinical trial. We have access to the long-term open-label data that has not been published yet. Obviously, we don't know the double-blind data. It is double-blind, but the open-label long-term study data is available. And we will be discussing on what will be the appropriate time to put those data in the public domain. Okay. Perfect. And then just a question in terms of and again, sorry if you mentioned this, but the 150 new patient adds, is there any seasonality impact here on the number of patient adds, or is it mostly the growth to net and that impact on the inventory also having an impact? Or does the number of patient adds also get impacted by seasonality in the Q1? Because we had seen it a few years ago. It was only 100 patients, I think, in Q1 2022. So just wondering about that. Then you mentioned the 700-720 guidance, but I don't think you mentioned the 7,000 patients on drug. Is that still something that we should expect, or are we getting away from that 7,000 number here? Thank you. Sure. Frank, thanks for the question. And yeah, from a Q1 perspective, we do see seasonal payer headwinds that do have an influence on the number of patient ads in the Q1. And you cited the 150 patient ads we had this quarter is in line with the last two years. We had 200 last year. We had 100 two years ago. So very consistent as we get reauthorization headwinds on prescriptions. And the one thing taken into account this year, Frank, is we had a larger established patient base coming into 2024. We had about 6,150 average patients that were exposed to that reauthorization this year, whereas coming into 2023, we only had 4,900. So we had about 25% more patients exposed to that reauthorization of prescriptions that most specialty and branded products face in January. And as you know, that simply adds time to the process, which does have a little bit of influence on patient ads, but it's in line with our expectations. We're extremely pleased with what we saw in the Q1. And then leading into your questions about guiding towards approximately 7,000 patients at the end of the year, in addition to reiterating our guidance on net sales, I am reiterating the guidance that we're expecting to end the year at around 7,000 average patients. Thank you. Thanks, Frank. We will take our next question from Ami Fadia with Needham. Hi. Good morning. Congrats on all the progress at the company along with the recent deals. My first question is on idiopathic hypersomnia. Could you share some of the details of the discussion that you had with the FDA and how they viewed some of the additional analysis that you were going to share with them? And did you specifically get clarity on whether these data would be adequate for approval, or was that characterized as a review issue by the FDA? And then I have one more question. Good morning, Ami. Thank you for your question. It's Jeff. Yeah, I think, as you know, we had a good interaction with the FDA regarding the IH program. And also, as you're aware, it always comes down to a review issue. But based on the discussion and interaction and the strength of the data that we generated, we feel that there is a path forward. And Kumar can share some more of the color around the FDA interaction. Yeah. Thank you, Jeff. Thank you, Ami, for the question. Yes, we had good discussions with the regulatory agency on the data, the unmet need, the lack of treatment options, and especially around the off-label use of controlled stimulants. We did feel that the FDA recognizes, acknowledges, and appreciates the lack of treatment options in patients with idiopathic hypersomnia. We are optimistic based on the totality of the data, Ami, not just the open label, but also the trends we saw in the randomized withdrawal period, and especially the long-term extension study, which I have mentioned earlier, where we still have approximately 90 patients in the long-term extension study. All of those patients have completed six months of treatment, and more than half of them have completed 12 months of treatment. About 10 of those patients have completed 18 months of treatment. We continue to see persistence of effectiveness. We are looking at not just the safety data, but also the effectiveness data as well. Combined with all of these things, in addition, we are also planning on obtaining real-world data and other data that will not just strengthen the submission, but also contextualize the data that was generated from the induced study. Based on all of this, we are optimistic. We do recognize the bar is high. But as Jeff has consistently mentioned, we are committed to patients with idiopathic hypersomnia to bring pitolisant to them as soon as possible, as efficiently as possible, and giving them an option for a non-scheduled drug with a simple dosing regimen and an established safety profile. Got it. That's very helpful. Just with regards to EPX-100, this class of drugs has had a history of some safety issues. And so could you comment on how you got comfortable with the safety profile of EPX-100, and if you could give us some color around the dose that's being studied in the trial relative to the dose that has been approved in the market for all these years? And also, if you could talk about the IP protection that you anticipate for the asset. Thank you. Yeah. Sure, Ami. I mean, I guess you were referring to some of the cardiovascular issues that Fintepla has, which also acts via a serotonergic mechanism of action. The serotonergic mechanism of action with this particular set of indications is a proven mechanism of action, particularly with the fenfluramine, which is the active ingredient in Fintepla, does show some cardiovascular effects like pulmonary arterial hypertension, which in turn results in thickening of the heart valves. That's why that particular product has a black box warning and is also subject to the REMS program. With the clemizole hydrochloride, there is a huge body of safety data from the time that it was introduced as a first-generation antihistamine in the 1950s, 1960s, and 1970s. On top of it, we conducted a full battery of non-clinical safety studies, including six-month studies, repeat dose studies in rats, nine-month repeat dose studies in dogs. As you know, dogs are extremely sensitive when it comes to the findings of cardiovascular issues. We did not see anything to suggest that the clemizole hydrochloride has any cardiovascular impact, including QTc. And then these data were reviewed by the FDA. And they did not ask us to conduct any additional cardiovascular monitoring apart from routine EEG and the monitoring of pulse and blood pressure. And on top of it, Ami, earlier, I mentioned that the patients who complete the double-blind randomized study roll into open-label extension study. And that's a three-year open-label extension study. And some of these patients have exposure past one year. And the safety profile looks pretty good in the sense none of them have had any cardiovascular issues. And also, we haven't seen any laboratory abnormalities as well. There are two drugs that are often used in this indication. One of them has significant GI issues and requests liver function monitoring on a regular basis. The other one, as I mentioned, has issues with the cardiovascular system. We haven't seen either of them. The safety profile is pretty benign. The efficacy data that we have seen in the open-label part is pretty compelling, potential to offer a very unique benefit-risk profile in this patient population. Thanks, Kumar. That was really helpful. I just had that IP question as well, if that's okay. Yeah. This is an old compound, Ami. So we don't have a composition of matter patent, but we do have a method of use patent. Of course, because both of these are orphan diseases, rare diseases, we will get seven years of orphan drug exclusivity in the U.S. for each of these indications. This is a global opportunity for us. So we will get 10 years of exclusivity in Europe for each of these indications. And just to clarify, Kumar, method of use out to 2034? 2034 and any other extension that we have. And the regulatory exclusivities. Perfect. Thanks very much. Thank you, Ami. And we will take our next question from David Amsellem with Piper Sandler. Hey, thanks. So I have two questions, one on clemizole and then one on the orexin. So on clemizole, so can you talk about how the product compares versus next-generation options with serotonergic activity? I'm thinking specifically of Longboard bexicaserin given its recent body of data. How do you think about how clemizole stacks up? And I understand it's a polypharmacy-based market, but do you think that there's room for these agents with some overlap mechanistically? So that's number one. And then number two, on the orexin, and I know it's early, but can you talk to the development path here? You've got Alkermes and you've got Takeda advancing their orexins in NT1 and Alkermes also in NT2. Do you think more about yours potentially in IH or in other settings where hypersomnolence is a hallmark symptom, or are you also looking at your garden variety path forward in terms of narcolepsy 1 and 2? Just help us better understand how you're thinking about it. Thank you. Thanks, David, for your questions. Kumar, you want to address on EPX-100, and then I'll respond to the orexin question, sure. Thank you, Jeff. Hey, good morning, David. David, thanks for the question. Regarding EPX-100, I guess you're referring to the data from the specific study, right, which was recently disclosed. Look, it's a small study, 52 patients. The efficacy data looked good. But it's also a short study too, and we haven't seen the long-term safety data yet as they continue to collect. So I see that as early stage still. And we just need to see how it will pan out as it goes to the next stage of development. And in this particular space, David, as you know, or as we mentioned just now, it's a polypharmacy market. That's significant unmet need. There is a place for different mechanisms of action to coexist. Even incremental differentiation in efficacy or safety is embraced by the providers and the patients alike. Yeah. And David, with regard to your question about TPM-1116 and our orexin-2 agonist, while we recognize that it's an early stage and the other development programs ahead, I think that we're still learning from. So I think that we are still learning from those data and those programs as they are generated. So with regards to our development plan and approach, I think we have optionality. I think that there'll be optionality based on what we learn from some of these other orexin development programs ahead. The most logical approach, I think, as you're aware, going in through NT1, which is the prototypical disorder with orexin deficiency as opposed to NT2 and IH. But we will learn from some of the other programs and have the optionality with regards to what the best path forward will be as we advance TPM-1116 for additional follow-up. Okay. Yeah. Thank you, Jeff. Yeah, just to add on. Look, Ami, the question regarding is it garden variety, NT1, NT2, or something else? David, this particular compound, TPM-1116, has a real high potency. And that actually provides us optionality in terms of looking at other central disorders of hypersomnolence as well. I mean, as you know, Takeda had to limit the dose to 10 milligrams, and they decided to only pursue NT1, not NT2, or idiopathic hypersomnia at this stage. The preclinical profile that we see with the TPM-1116 looks pretty good. And based on that, we do see optionality here other than the routine central disorders of hypersomnolence. Thanks, Kumar. All right. Thanks, guys. Thanks, David. We will take our next question from Graig Suvannavejh with Mizuho. Great. Thank you. Can you hear me okay? Yes, we can. Great. Good morning. Okay. Thanks, Jeff. Congrats on the great progress that we're seeing from the company. I've actually got a question for Sandip. Sandip, just so in light of the new BD deals that you've done and your plans to potentially continue adding to the pipeline, I guess it's a two-part question. First, or maybe, Jeff, you can answer this first part of the question. Is the current plan on any next deal that you do to first prioritize on adding yet another or a fourth CNS franchise, or is the current plan or your thoughts currently to build on the existing three CNS franchises you have now? Then the second part of my question, maybe this is really more for Sandip, is in light of kind of the added pipeline programs, which is, I think, we all think is in a positive, just wondering if you've got any initial thoughts on what the P&L might look like for the company, both in terms of SG&A and R&D for Harmony over the next one or two, three years. Thanks. Sure, Greg. Yeah, let me address your first question. In terms of sort of the BD, our growth strategy going forward, again, I think it's also optionality again. I'm very pleased with how we've been able to expand and grow the pipeline, diversify our portfolio, and these three CNS franchises where we are now, each with potential peak sales opportunities of $1 billion-$2 billion. We could either, based on we continue to be active in BD and looking at the landscape, so we could go further in either of these franchises with additional assets, or if we see another opportunity in another CNS area that we could diversify the pipeline further, we are that would be another path forward. The other thing I want to comment on and to, I think, just bring light to, this approach also is important that it leverages our internal expertise in the CNS area as well as the commercial model, our internal synergies. So as we expand and diversify this portfolio in these CNS areas, then just our commercial model where we could thoughtfully apply that model to any new indications, any new products that would go to market. So I think that's how we're seeing the strategy going forward. Pleased with the progress to date, but we're not stopping there. Sandip, you want to? Yeah, sure. With respect to your question in terms of the financial impact overall, as you saw from both of the deals, look, we continue to be very disciplined in capital deployment. We've structured them with low upfront relative to the stage of the assets with more success-driven milestones. These are all fairly late-stage programs. So in terms of actual capital resources, we're really for the next couple of years if you just think about it. And also, we've got growing revenues. We've got internal synergies overall that we can also bring and growing profitability that gives us the capacity to continue to do additional business development opportunities while still maintaining a relatively profitable business that's self-sustaining and can continue to grow. So I think I feel good about what we've been able to acquire. These are, again, very late-stage assets. Like I mentioned, for this year, it's about $35 million more in terms of incremental cost and probably similarly as you go into next year, and we'll get those top lines. So really a good, smart investment upfront to hopefully unlock incremental value. Operator, next question. We will take our next question from Corinne Johnson with Goldman Sachs. Please go ahead. Your line is open, Corinne Johnson. Sorry, I was on mute. Good morning, guys. Can you just help us understand how you thought about the market opportunity and potential value for these assets, EPX-100 and 200? And in particular, how do you think about the vast differentiation there? And with that differentiation, what kind of the peak sales opportunity could be for such an asset? Good morning, Corinne. So in terms of the market opportunity, referring to Epygenix and the rare epilepsy franchise, so I think, obviously, the epilepsy space is significant market opportunity beginning in this area of orphan rare and the developmental epileptic encephalopathies. We are in the registration trial for Dravet, kind of a smaller patient population, but planning to initiate a phase III study in Lennox-Gastaut syndrome second half of this year, a larger market opportunity. But we also see this acquisition as sort of the foundation of a broader epilepsy franchise. So with regards to current market opportunity with regards to what's currently available, I think as Kumar has been alluding to, we see the potential product profile of EPX-100 in terms of overall benefit-risk compared to the current treatment options as a significant product offering in terms of therapeutic option in the near term. And then we look to draw on our internal sort of expertise in this area, look for potentially additional assets to build out a broader epilepsy franchise. And I think that's the current view on where we are on there. Kumar, any other thoughts? Yeah. I mean, as I mentioned earlier, based on what we have seen, we believe that it will offer a compelling value proposition with a unique benefit-risk profile for patients, especially from a safety profile given some of the significant limitations we see with some of the drugs that are currently approved in this space. Okay. Yeah. And we will take our next question from Jason Gerberry with Bank of America. Hey, guys. Good morning. Thanks for taking my question. I guess one question on EPX-100. Is the base case here that you have the same class safety labeling around CV tox as Fintepla? I'm seeing in the preclinical, there's some affinity for 5-HT2B. So just wondering that coupled with it's only a 100-patient pivotal study, if you can or think you may be able to decouple that safety issue from a safety labeling perspective. And then from a development perspective, are you planning to run a second pivotal trial? Would that be done in parallel once you get the asset in-house, or would that be after you get data in 2026? Just wondering sort of the timeline to market for EPX-100. Thanks. Good morning, Jason. Yeah, thank you for your question. Yeah, I think Kumar can sort of unpack that with regards to the opportunity that we're seeing near-term with regards to Dravet. And then in terms of differentiated from a safety perspective with regards to Fintepla. Yeah. Jason, good morning, and thanks for the question. I mean, the answer to your first question is that no. We do not anticipate any cardiovascular liability with clemizole hydrochloride. That is based on the large body of data from the first-generation antihistamine and then all the preclinical data that we have generated for this particular compound, including repeat dose, chronic tox studies in the preclinical space. And also, looking at the data, the FDA did not require to do echocardiogram or monitor for pulmonary arterial hypertension or cardiac valvular abnormalities. So we do not believe that this will have any of the safety issues that we do see with Fintepla, which has a black box warning and is subjected to REMS programs. And also, based on the long-term extension study open-label data, Jason, that we have seen so far, we are actually very pleased with the safety profile, both in terms of lack of any lab abnormalities and also from the cardiovascular safety perspective and just safety and tolerability in general. And to your second question about the second study, the current study, Jason, I know that on clinicaltrials.gov, it still says it as phase II study, but it's actually a registration phase III study. It started out as a phase II study, and then the sample size was increased to 100 subjects, equally randomized 1:1 between clemizole and placebo. And now this is a pivotal registration study, and the top-line data will be available in 2026. And typically, Jason, as you know, in rare disorders, one adequate and well-controlled study is generally accepted as substantial evidence for effectiveness by the regulatory agencies. So we do plan to file based off of this study should the data look good. Got it. Okay. Thank you. Thanks, Jason. Thanks, Jason. And we will take our last question from Danielle Brill with Raymond James. Hi, guys. Good morning. Thanks for the question. I'm curious how you're gauging the TPM-1116 profile versus the other orexin agonists, and what type of data should we expect to be presented at the upcoming scientific meeting, and which conference are you targeting? Thank you. Thanks, Danielle, for your question. Kumar? Sure. Hey, good morning, Danielle. Thanks for the question. Yeah, just some background information, Danielle. On TPM-1116, this originated out of Teijin Pharma. This is a conglomerate with deep expertise in drug discovery. They actually worked very closely with Professor Yanagisawa, who many of you know is the one who actually discovered orexins and their impact on sleep-wake. They have been working on this series of compounds for a while, and they advanced TPM-1116 because that was the best in the series that they found. TPM-1116 has a very novel chemical scaffold compared to the other orexins and receptor agonists that are out there. And we believe that this novel chemical scaffold offers certain unique features that we have seen in our preclinical studies. First and foremost, high potency, good selectivity, potential for once-a-day dosing, and good preclinical safety data. We are completing the rest of the IND-enabling experiments, and we plan to submit IND mid-2025 and start first-in-human studies in the second half of 2025. Thank you. I am showing no further questions. I would now like to turn the call back for any closing remarks. Thank you, Madison. Thanks, everyone, for joining our call today and for your interest in Harmony. As you heard from us this morning, the future is bright at Harmony, based on the strength of our commercial business of WAKIX and narcolepsy and the value of our expanding pipeline, which will serve as the foundation for durable revenue generation out beyond 2040. We look forward to providing updates as we continue to accelerate our strategy for long-term growth. Thank you, and have a great day. This does conclude today's Harmony Biosciences Q1 2024 Financial Results Conference call. You may now disconnect your line and have a wonderful day.